154 related articles for article (PubMed ID: 9832291)
1. Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients.
Jonsson E; Fridborg H; Nygren P; Larsson R
Eur J Clin Pharmacol; 1998 Sep; 54(7):509-14. PubMed ID: 9832291
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
Romanelli S; Perego P; Pratesi G; Carenini N; Tortoreto M; Zunino F
Cancer Chemother Pharmacol; 1998; 41(5):385-90. PubMed ID: 9523734
[TBL] [Abstract][Full Text] [Related]
3. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design.
Chou TC; Motzer RJ; Tong Y; Bosl GJ
J Natl Cancer Inst; 1994 Oct; 86(20):1517-24. PubMed ID: 7932806
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines.
Kaufmann SH; Peereboom D; Buckwalter CA; Svingen PA; Grochow LB; Donehower RC; Rowinsky EK
J Natl Cancer Inst; 1996 Jun; 88(11):734-41. PubMed ID: 8637027
[TBL] [Abstract][Full Text] [Related]
5. Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines.
Janss AJ; Cnaan A; Zhao H; Shpilsky A; Levow C; Sutton L; Phillips PC
Anticancer Drugs; 1998 Aug; 9(7):641-52. PubMed ID: 9773809
[TBL] [Abstract][Full Text] [Related]
6. Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
Kawano M; Mabuchi S; Kishimoto T; Hisamatsu T; Matsumoto Y; Sasano T; Takahashi R; Sawada K; Takahashi K; Takahashi T; Hamasaki T; Kimura T
Int J Gynecol Cancer; 2014 Jun; 24(5):829-37. PubMed ID: 24844217
[TBL] [Abstract][Full Text] [Related]
7. Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
Reddy JA; Dorton R; Bloomfield A; Nelson M; Vetzel M; Guan J; Leamon CP
Clin Cancer Res; 2014 Apr; 20(8):2104-14. PubMed ID: 24429878
[TBL] [Abstract][Full Text] [Related]
8. Identification of cisplatin sensitizers through high-throughput combinatorial screening.
Sun Y; Jiang W; Lu W; Song M; Liu K; Chen P; Chang A; Ling J; Chiao PJ; Hu Y; Huang P
Int J Oncol; 2018 Sep; 53(3):1237-1246. PubMed ID: 29956742
[TBL] [Abstract][Full Text] [Related]
9. Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience.
Kollmannsberger C; Mross K; Jakob A; Kanz L; Bokemeyer C
Oncology; 1999; 56(1):1-12. PubMed ID: 9885371
[TBL] [Abstract][Full Text] [Related]
10. Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin.
van Waardenburg RC; de Jong LA; van Eijndhoven MA; Verseyden C; Pluim D; Jansen LE; Bjornsti MA; Schellens JH
J Biol Chem; 2004 Dec; 279(52):54502-9. PubMed ID: 15471886
[TBL] [Abstract][Full Text] [Related]
11. Synergistic interaction between topotecan and microtubule-interfering agents.
Bahadori HR; Green MR; Catapano CV
Cancer Chemother Pharmacol; 2001 Sep; 48(3):188-96. PubMed ID: 11592339
[TBL] [Abstract][Full Text] [Related]
12. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
13. Topotecan in combination chemotherapy.
Rowinsky EK; Kaufmann SH
Semin Oncol; 1997 Dec; 24(6 Suppl 20):S20-11-S20-26. PubMed ID: 9425957
[TBL] [Abstract][Full Text] [Related]
14. Combination screening in vitro identifies synergistically acting KP372-1 and cytarabine against acute myeloid leukemia.
Österroos A; Kashif M; Haglund C; Blom K; Höglund M; Andersson C; Gustafsson MG; Eriksson A; Larsson R
Biochem Pharmacol; 2016 Oct; 118():40-49. PubMed ID: 27565890
[TBL] [Abstract][Full Text] [Related]
15. Interactions between cladribine (2-chlorodeoxyadenosine) and standard antileukemic drugs in primary cultures of human tumor cells from patients with acute myelocytic leukemia.
Kristensen J; Nygren P; Liliemark J; Fridborg H; Killander A; Simonsson B; Oberg G; Larsson R
Leukemia; 1994 Oct; 8(10):1712-7. PubMed ID: 7934168
[TBL] [Abstract][Full Text] [Related]
16. Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.
Schwartz GN; Teicher BA; Eder JP; Korbut T; Holden SA; Ara G; Herman TS
Cancer Chemother Pharmacol; 1993; 32(6):455-62. PubMed ID: 8258194
[TBL] [Abstract][Full Text] [Related]
17. Synergistic cytotoxicity of pyrazoloacridine with doxorubicin, etoposide, and topotecan in drug-resistant tumor cells.
Hu Y; Krishan A; Nie W; Sridhar KS; Mayer LD; Bally M
Clin Cancer Res; 2004 Feb; 10(3):1160-9. PubMed ID: 14871996
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration.
Bible KC; Kaufmann SH
Cancer Res; 1997 Aug; 57(16):3375-80. PubMed ID: 9269999
[TBL] [Abstract][Full Text] [Related]
19. Synergy between the herpes simplex virus tk/ganciclovir prodrug suicide system and the topoisomerase I inhibitor topotecan.
Wildner O; Blaese RM; Morris JC
Hum Gene Ther; 1999 Nov; 10(16):2679-87. PubMed ID: 10566896
[TBL] [Abstract][Full Text] [Related]
20. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro.
Ma J; Maliepaard M; Nooter K; Boersma AW; Verweij J; Stoter G; Schellens JH
Cancer Chemother Pharmacol; 1998; 41(4):307-16. PubMed ID: 9488600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
